Streetbeat News

Products Services

PDSB

PDS Biotechnology Corporation announced promising results from its VERSATILE-002 trial, showing that its Versamune HPV in combination with KEYTRUDA® significantly improves survival rates and response rates in HPV16-positive head and neck cancer patients. The trial results were presented at the ESMO Congress 2024, and a Phase 3 trial is planned.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:06 am

GILT

DataPath, a subsidiary of Gilat Satellite Networks, has secured contracts worth over $5 million to support the US Department of Defense. The contracts involve sustainment and technical upgrades to Satellite Transportable Terminal units, enhancing military operations.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:06 am

NSPR

InspireMD has submitted a premarket approval application to the FDA for its CGuard Prime Carotid Stent System. If approved, the company anticipates a US commercial launch in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:05 am

PASG

Passage Bio, Inc. (NASDAQ:PASG) will present new data on its gene therapy PBFT02 for frontotemporal dementia at ISFTD2024. The data from the Phase 1/2 upliFT-D trial shows promising safety and biomarker results, with no serious adverse events reported.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:05 am

GOGO

Gogo Business Aviation (NASDAQ:GOGO) has expanded its partnership with Airshare, offering 5G and satellite Wi-Fi services for business aviation. The multi-year agreement allows Airshare's aircraft management clients to install Gogo's AVANCE, 5G, and Galileo services, enhancing connectivity for private flights.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:04 am

EVAX

Evaxion Biotech reported promising one-year data from its Phase 2 trial of EVX-01, a personalized cancer vaccine. The trial showed a 69% overall response rate, with 15 out of 16 patients experiencing tumor reduction. The vaccine's targets triggered a strong immune response, indicating significant commercial potential for melanoma treatment.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:03 am

AZN

AstraZeneca's HIMALAYA Phase III trial results show that the dual therapy of IMFINZI and IMJUDO significantly improves 5-year survival rates for patients with unresectable hepatocellular carcinoma. The STRIDE regimen reduced the risk of death by 24% compared to sorafenib, marking a major advancement in liver cancer treatment.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:02 am

NYAX

Nayax partners with Adyen to integrate its payment and loyalty platform into Adyen's global platform, expanding into new regions and reducing operational costs.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:02 am

KTOS

Thaicom Public Company has awarded Kratos a multi-million dollar contract to provide an end-to-end ground system for its new software-defined satellite, THAICOM-10. This system will allow Thaicom to optimize satellite and ground system configurations to deliver on-demand services.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:01 am

PLL

Piedmont Lithium has received an environmental permit from Ghana's EPA for the Ewoyaa Lithium Project, developed in partnership with Atlantic Lithium. Piedmont has also increased its stake in the project, aiming for a 50% equity interest.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:53 am